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In a murine model of allergic asthma, we found that Tyk-2(2/2) asthmatic mice have induced peribronchial
collagen deposition, mucosal type mast cells in the lung, IRF4 and hyperproliferative lung Th2 CD41
effector T cells over-expressing IL-3, IL-4, IL-5, IL-10 and IL-13. We also observed increased Th9 cells
expressing IL-9 and IL-10 as well as T helper cells expressing IL-6, IL-10 and IL-21 with a defect in IL-17A
and IL-17F production. This T helper phenotype was accompanied by increased SOCS3 in the lung of Tyk-2
deficient asthmatic mice. Finally, in vivo treatment with rIL-17A inhibited local CD41CD251Foxp31 T
regulatory cells as well as Th2 cytokines without affecting IL-9 in the lung. These results suggest a role of
Tyk-2 in different subsets of T helper cellsmediated by SOCS3 regulation that is relevant for the treatment of
asthma, cancer and autoimmune diseases.
I
n mammals cytokines signal primarily through signaling pathways involving cytokine-receptor-activated
Janus kinases (JAKs 1–3 and Tyrosine kinase 2) and STAT (Signal and Activators of Transcription 1–6)
transcription factors1. Tyk-2 has been first described by Velazquez et al.2 and it is known to be involved in
interleukins IL-6, IL-10, IL-11, IL-12, IL-13, IL-22, IL-23, IL-27, IL-31 and IFN (interferon) a, b and l signal
transduction3,4. However, IL-6 and IL-10 mediated signal transduction is still functional in Tyk-2(2/2) mice5,6.
Tyk-2 deficiency in humans has been found to be associated with an increased susceptibility to viral and
mycobacterial infections as well as atopic dermatitis, hypereosinophilia and Hyper IgE syndrome7. These symp-
toms hint towards a Th2-skewed cytokine profile in the absence of Tyk-2 function. As these cytokines play a
major role in the pathogenesis of allergic diseases such as asthma, we analyzed Tyk-2(2/2) mice in amurine model
of allergic asthma8.
Allergic asthma is an inflammatory disease of the airways which occurs with increased prevalence during the
last decades especially in the developed world9,10. However, themolecularmechanism of this disease needs further
investigations. Recently, the role of IL-17A and IL-9 in an experimental model of asthma has been further
explored. IL-9 was first characterized as a T cell and mast cell growth factor11. Transgenic expression of IL-9
in the lung results in allergic inflammation dependent on Th2 cytokines12. Moreover, blockade of IL-9 inhibits
mastocytosis and airway remodeling13. Th9 cells are induced by TGF-b and IL-414.
IL-17A was found to play a pathogenetic role during the developmental phase of the disease, while it amelio-
rates established allergic disease15. Since IL-17A is a known neutrophil attracting cytokine, it has been hypothe-
sized that it is more associated with neutrophil-dominated allergic asthma16,17. This form of the disease is known
to be more severe and difficult to treat than eosinophil-dominated asthma. Additionally, IL-17A has also been
identified to be a main causative agent for the occurrence of airway hyperreactivity, one of the key hallmarks of
allergic asthma16,18,19. The suppressor of cytokine signalling (SOCS)-3 activation, inhibits several cytokine signal-
ing in T helper cells as well as in dendritic cells thus regulating and having a significant impact on the development
of the downstream immune responses20.
Here, we show that Tyk-2(2/2) mice have hypereosinophilia and hyper IgE associated with increased remodel-
ing, mast cells, effector Th2 and Th9 cells in the airways. This phenotype was found to be associated with a defect
in Th17 cell polarization. Moreover, in the lung of asthmatic Tyk-2 deficient mice, protein level was found up-
regulated. Treatment with rIL-17A led to a down-regulation of Th2 andT regulatory cells in the lung of Tyk-2(2/2)
mice. In conclusion, Tyk-2 plays a fundamental role downstream of many cytokine receptors in controlling
allergic asthma by limiting different subsets of T helper cell derived cytokines such as IL-6, IL-9 and IL-21 and
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inducing IL-17A and IL-17F. Tyk-2 in asthma probably regulates
these cytokines in the presence of suppressed levels of SOCS3.
Results
Tyk2 deficiency leads to a severe Th2 allergic phenotype after
allergen challenge. Allergic asthma induced in Tyk2 deficient
mice, leads to severe infiltration of eosinophils in the BALF as
compared to the wild type littermates mice (Fig. S1a–c). This effect
is probably mediated by the increase of IL-5, the eosinophil growth
and differentiating factor (Fig. S1 d). Tyk2 deficiency is also known to
be associated with hyper IgE production7 (Fig. S1e). Along with
hyper-IgE these mice also displayed elevated levels of IgG2A com-
pared to wild type mice (Fig. S1f). In spite of elevated Th2 cytokines
and inflammation in the airways, Tyk-2 deficient mice did not show
increased airway hyperresponsiveness to methacholine after allergen
sensitization and challenge (Fig. S1g).
We also detected induced fibrosis in the lung of Tyk2(2/2) mice
after allergen sensitization and challenge (Fig. S1h). Consistent with
these findings, lung CD41 T cells isolated from the Tyk-2 deficient
mice released increased amounts of IL-13, a Th2 cytokine which
favors fibrosis, as compared to wild type littermates (Fig. S 1i).
IncreasedTh9 andmast cell number in the lung of Tyk-2(2/2) mice.
Mast cells are major players in the induction of allergic diseases such
as asthma. Since it has been previously described that Tyk-2(2/2) mice
show an increased Th2 differentiation and thus a more severe
asthmatic phenotype21, we analyzed the number of mast cells in
Tyk-2(2/2) mice after allergen treatment. In a murine model of
allergic asthma (Fig. 1a), we thus analyzed the lung section stained
with Toluidine Blue, a specific staining for mast cells, and found an
increased number of positive cells in the absence of Tyk-2 (Fig. 1b).
We then analyzed total lung cells by flow cytometry. Mast cells were
defined as c-kithiCD1231FceRI1 cells gated on SSChic-kithi. These
mast cells are known as mucosal mast cells as they express the IL-
3R (CD1231). The analysis showed a significant up-regulation of
mast cells in Tyk-2(2/2) mice after allergen challenge (Fig. 1c)
identifying mucosal mast cell number as a possible explanation for
the allergic phenotype of these mice.
Finally, we looked at the concentrations of the twomain mast cell-
inducing cytokines, IL-3 and IL-9. Further analysis showed that lung
CD41 T cells from Tyk-2(2/2) mice released significantly more IL-3
(Fig. 1d) and IL-9 (Fig. 1e) as well as IL-10 (Fig. 1f and 1g) after
ovalbumin challenge. Analysis of the recently found Th9-defining
transcription factor interferon-regulatory factor 4 (Irf4), which also
Figure 1 | Tyk-2 deficiency inducedmast cell differentiation and IL-9 in the lung of asthmaticmice. (a). experimental design (b). Lung histology formast
cell detection with Toluidine Blue staining. (c). Total lung cells from naı¨ve and OVA treated mice were incubated with antibodies against CD117
(c-kit), CD123 (IL-3Ra) and FceRI and analyzed by flow cytometry (n5 2–4; p5 0.05). (d).–(f). Lung CD41T cells from naı¨ve (PBS) and OVA treatedmice
were isolated and incubated for 24 h with a-CD3 and a-CD28 antibodies. The supernatants were analyzed by ELISA for IL-3 (d), IL-9 (e) and IL-10 (f)
((d): n 5 4; p 5 0.002; p 5 0.004; (e): n 5 3–4; p 5 0.037; p 5 0.015; p 5 0.024; (f): n 5 3; p 5 0.012, respectively) (g). Release of IL-10 by total lung cells
((g): n 5 3; p 5 0,049; p 5 0,02) (h). and (i). Irf4 and Pu.1 mRNA expression in total lung ((h): n 5 2–4; p 5 0,001 p 5 0,007; (i): n 5 3–4).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5865 | DOI: 10.1038/srep05865 2
regulates Th2 and Th17 cell differentiation22,23 also revealed induced
expression levels after allergen challenge in Tyk-2(2/2) mice com-
pared to wild-type mice in total lung (Fig. 1h). Finally, the most
recognized Th9 transcription factor Pu.124 was also found up-
regulated at the mRNA level in the lung of Tyk-2 deficient mice
(Fig. 1i). These data show an increased number of mast cells and mast
cell growth factors such as IL-3 and IL-9 in the lung of Tyk-2(2/2) mice.
Increased proliferation of lung CD41 T cells isolated from Tyk-
2(2/2) asthmatic mice. To investigate the role of Tyk-2 in T cells in a
setting of allergic asthma, we sorted out lung CD41 T cells from
asthmatic mice and analyzed their proliferation after CFSE
staining in a four days cell culture. As shown (Fig. 2 a and b),
CD41 T cells isolated from the lung of Tyk-2(2/2) mice proliferated
more than those from the lung of wild type littermates, indicating
increased effector T cells in the absence of Tyk-2. We then analyzed
IL-6, a T regulatory cell inhibiting cytokine25, and found it elevated in
the supernatants of cultured lung CD41 T cells in the absence of Tyk-
2 in experimental allergic asthma (Fig. 2c). Similarly, IL-21, a
cytokine known to counteract T regulatory cells26, was found
increased in the supernatants of lung CD41 T cells of Tyk-2(2/2)
mice (Fig. 2d), while TGF-b, a T regulatory inducing cytokine was
found unchanged before and after allergen challenge (Fig. 2e,f). The
Th9 subset differentiates in vitro by the addition of TGF-beta and
IL-427. We next analyzed IL-4 which, consistent with a role of Tyk-2
in Th2 cells, was found significantly up-regulated in the supernatants
of lung CD41 cells isolated from the Tyk-2(2/2) mice as compared to
those isolated from wild type littermates (Fig. 2g). Taken together,
these data support a central role of Tyk-2 in inhibiting Th9
differentiation and in general its T cell anti-proliferative function
in allergic asthma.
Increased SOCS3 in the lung of Tyk-2(2/2) mice in amurinemodel
of allergic asthma. IL-9 was originally identified as a T cell growth
factor and it is a member of the common-c-chain-receptor cytokine
family including IL-2, IL-4, IL-7, IL-15 and IL-21. The activation of
IL-9 receptor a-c-chain induces activation of JAK/1–3 and
downstream STAT1/3 and STAT528. It has been demonstrated that
IL-9 induces SOCS3 which then limits IL-9 signaling29. Considering
that IL-6, IL-21, IL-4 and IL-9 were found elevated in asthma
Figure 2 | Tyk-2 inhibited T cell proliferation in asthma. (a). and (b). CFSE labelled spleen CD41 T cells from naı¨ve and asthmatic Tyk-2(2/2) mice were
analyzed for their proliferation (n5 4–5;M5Mitosis:M1: p5 0,0000,M2: p5 0,0000,M3: p5 0,0001,M4: p5 0,0005,M5: p5 0,0459). (c–e). CD41T
cells were isolated from the lungs of naı¨ve and OVA-treated wild type and Tyk-2(2/2) mice and cultured for 24 h with a-CD3 and a-CD28 antibodies and
supernatants were analyzed by ELISA for IL-6 ((c): n 5 2–3; p 5 0.0014, p 5 0,0053, p 5 0,0052), IL-21 ((d): n 5 2–3; p 5 0.0015), TGF-b ((e): n 5 3)).
(f). TGF-b levels in the supernatants of total lung cells (n5 3). (g). CD41 T cells were isolated from the lungs of naı¨ve andOVA-treated wild type and Tyk-
2(2/2) mice and cultured for 24 h with a-CD3 and a-CD28 antibodies and supernatants were analyzed by ELISA for IL-4 (n 5 2–4; p 5 0,019 p 5 0,005
p 5 0,001 p 5 0,0046). (h). Total lung cells from wild type and Tyk-22/2 mice were incubated with antibodies against CD4 and pSTAT3 (n 5 4–5;
p5 0.002) and analyzed by flow cytometry. (i). Total lung RNAwas analyzed after cDNA synthesis by qPCR for the expression of Stat5mRNA (n5 3). (j).
Western blot analysis was performed on total lung protein extracts from OVA-treated mice. The membrane was probed with antibodies against SOCS3
and b-Actin as normalization control (n 5 5; p 5 0.00003).
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particularly in the absence of Tyk-2, we then looked at the
downstream signal of these cytokines. First, we looked at pSTAT3
which is activated by IL-9 and IL-6. Although it was found elevated in
the lung of Tyk-2(2/2) asthmatic mice, no difference was observed
between wild type and Tyk-2 deficient mice (Fig. 2h). STAT5mRNA
was also not found significantly regulated by Tyk-2 in this disease
model (Fig. 2i). By contrast, SOCS3 protein was found significantly
up-regulated in the lung of asthmatic Tyk-2(2/2) mice (Fig. 2j).
Altogether, these data underline a role of IL-9 mediated by SOCS3
in the lung of Tyk-2 deficient mice.
Tyk-2 deficiency is associated with reduced IL-17A and IL-17F
production after allergen challenge. We next analyzed IL-17A
and IL-17F levels which we found to be down-regulated in Tyk-
2(2/2) mice after allergen challenge (Fig. 3a, b) as well as in naı¨ve
mice (Fig. 3c) compared to wild-type mice.
Next, we looked at the production of the cytokines relevant for
Th17 development. IL-1b productionwas analyzed in total lung cells.
We could observe a significant increase of this cytokine after allergen
challenge in Tyk-2(2/2) mice (Fig. 3d). Furthermore, in the BALF of
naı¨ve Tyk-2(2/2) mice we could detect higher amounts of IL-21
(Fig. 3e) and IL-23 (Fig. 3f) than in naı¨ve wild-type mice. After
allergen challenge, IL-21 and IL-23were found down-regulated espe-
cially in the BALF of Tyk-2(2/2) asthmatic mice. These data on IL-21
are similar to the findings on IL-10. In fact, IL-21 was found up-
regulated in the supernatants of lung CD41 T cells after allergen
challenge but down-regulated in the BALF. This might be due to
IL-21 release by different cell types.
Th17 differentiation is impaired in Tyk-2(2/2) mice. Tyk-2 is
located downstream of IL-6 and IL-23 signaling that are crucially
involved in the generation and proliferation of Th17 cells4,30,31. We
thus wanted to determine whether alternative pathways were
involved in the development of Th17 cells in the absence of Tyk-2.
To this aim we isolated splenic CD41CD62L1 T cells and exposed
them to Th17 skewing cell culture conditions (a-CD3, a-CD28,
Figure 3 | Tyk-2(2/2) mice showed a defective Th17 cytokine production in vivo. (a). and (b). Mice were treated with OVA as described in the
methods section. After 21 days themice were sacrificed and total cells were isolated from the lung. After 24 h incubation with antibodies against CD3 and
CD28 supernatants were analyzed by ELISA for IL-17A ((a): n 5 2–4, p 5 0,041; p 5 0,007) and IL-17F ((b): n 5 2–4, p 5 0,046, p 5 0,046). (c). Total
lung cells from untreated mice were isolated and incubated with antibodies against CD4 and IL-17A and analyzed by flow cytometry. Data show on the
one hand, lung IL-17A1CD41 T cells (left panel n 5 3–4, p 5 0,0003) and on the other hand lung IL-17A1CD42 cells (right panel n 5 3–4, p 5 0,003).
(d). Total lung cells from naı¨ve and allergen-treated mice were incubated with a-CD3 and a-CD28 antibodies for 24 h and analyzed by ELISA for IL-1b
production (n 5 2–4, p 5 0,009). (e). and (f). IL-21(n 5 4–5, p 5 0,025; p 5 0,0019; p 5 0,041; p 5 0,002) and IL-23 (n 5 3–5, p 5 0,045; p 5 0,038;
p 5 0,043; p 5 0,012) levels were measured in the BALF of naı¨ve and asthmatic mice.
www.nature.com/scientificreports
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a-IL-4, a-IFNc antibodies) in the presence of either IL-6 or either IL-
21 or IL-23 and TGF-b (Fig. 4a). Under all these experimental condi-
tions IL-17A production was found significantly reduced in naı¨ve
CD41 T cells isolated from Tyk-2(2/2) mice as compared to cells
isolated from the wild type littermates regardless of the cytokine milieu.
IL-10 was found significantly elevated in the Tyk-2(2/2) cells
treated with rTGF-b and rIL-6 (Fig. 4b).
By contrast, IL-17F was found to be significantly reduced in Tyk-
2(2/2) cells treated with rTGF-b plus either rIL-21 or rIL-6 and rIL-21
or rIL-23 (Fig. 4c).
These data are consistent with a recently described IL-17A inhib-
itory function of SOCS332.
Treatment of Tyk-2(2/2) mice with recombinant IL-17A in a
murine model of asthma reduced T regulatory cells. To analyze
the role of IL-17A deficiency in the absence of Tyk-2, we thought to
treat Tyk-2 deficient mice intranasally with recombinant murine IL-
17A in a murine model of allergic asthma.
Intranasal application of rIL-17A (Fig. 5a) led to a down regulation
of the Th2 cytokines IL-4, IL-5 and IL-13 only in Tyk-2(2/2) mice
(Fig. 5b–d, respectively). IL-17A is important for the recruitment of
neutrophils to the lung during allergic airway disease33. We thus
analyzed the number of neutrophils in BAL cells of naı¨ve mice and
after allergen challenge. We detected a defect of neutrophils in the
lung of Tyk-2(2/2) mice after allergen challenge. In vivo intranasal
application of recombinant IL-17A induced neutrophils in wild type
and less inTyk-2(2/2) mice (Fig. 5e). The latter result is consistent
with a role of IL-17A on neutrophilia and with defective IL-17A in
the lung of Tyk-2 deficient mice. Application of IL-17A andOVA led
to a down-regulation of T regulatory cells in Tyk-2(2/2) mice, whereas
the number of these cells remained unchanged in wild-type mice
(Fig. 5f). Thus, Tyk-2(2/2) mice had fewer regulatory T cells after
IL-17A treatment than wild type mice consistent with a role of
Tyk-2 in the generation of T regulatory cells downstream of the
IL-17A receptor.
When we analyzed the samples for IL-9 expression. We could
detect similar IL-9 levels in lung CD41 T cells (Fig. 5g) irrespective
of the treatment with rIL-17A. Taken together, these data dem-
onstrate that the exogenous IL-17A can induce neutrophilia in the
lung in the presence or absence of Tyk-2 and inhibit T regulatory
cells in the absence of Tyk-2.
Discussion
Here, we report a crucial protective regulatory role of Tyk-2 in
allergic asthma. In this study, we analyzed the role of Tyk-2 on IL-
9 production and on Th17 polarization in Tyk-2(2/2) mice com-
pared to wild type mice. Tyk-2(2/2) mice produced more IL-9 and
Irf4 and less of the Th17-hallmark cytokine IL-17A in vitro. We
confirmed these observations in vivo in a murine model of allergic
asthma, after allergen challenge. To analyze this finding more
closely, we looked at the expression of signaling molecules rel-
evant for IL-9 and IL-17A production. The Th17-inducing and
T regulatory cell inhibiting cytokines IL-6 and IL-21 were found
up-regulated in the absence of Tyk-2 in the supernatants of lung
CD41 T cells. The expression of SOCS3 is tightly regulated at the
protein level. SOCS3 transcription is rapidly induced by a range of
type I and type II cytokines, signaling via STAT1 and/or STAT3.
The best characterized inducers are members of the gp130 family,
including IL-6, IL-11 and LIF. Here, we describe for the first time
Figure 4 | Tyk-2(2/2) naı¨ve CD41 T cells showed a defective Th17 cytokine production ex vivo. Spleen CD41CD62L1 T cells were isolated from naı¨ve
Tyk-2(2/2) and wild-type mice and treated with antibodies against CD3 (2 mg/ml), CD28 (2 mg/ml), IL-4 (10 mg/ml) and IFNc (10 mg/ml) while
recombinant cytokines TGF-b (3 ng/ml), IL-6 (20 ng/ml), IL-23 (50 ng/ml) and IL-21 (80 ng/ml) were added as indicated. After five days the
supernatant was collected and analyzed by ELISA for IL-17A ((a): n 5 2, p 5 0,004, p 5 0,009, p 5 0,0008, p 5 0,0003, p 5 0,006) IL-10 ((b): n 5 2,
p 5 0,003) and IL-17F ((c): n 5 2, p 5 0,001, p 5 0,004, p 5 0,0003).
www.nature.com/scientificreports
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elevation of SOCS3 in the lung of Tyk-2 deficient mice. SOCS3 is
thought to play an important role in determining T cell res-
ponses34. The data presented in this manuscript are consistent
with an elevation of SOCS3 in DCs which limits the tolerogenic
effect of DCs thus inducing T effector cells20,35.
SOCS3 deficient DCs have been shown to give rise to more effec-
tive T regulatory cells. Thus SOCS3 induces the development ofmore
effector T cells such as Th2 and Th9 in the absence of Tyk-2. By
contrast, the T regulatory cells are inhibited in the presence of SOCS3
in DCs.
IL-10 was induced in lung CD41 T cell supernatants from Tyk-
2(2/2) mice after allergen challenge. IL-10 is a cytokine which is also
produced by T regulatory cells, Th2, Th9 and Th17 cells.
Mast cells are an important cell type in the pathophysiology of
allergic asthma. We then analyzed the presence of mast cell indu-
cing cytokines IL-3 and IL-9 and found that they were elevated in
Tyk-2(2/2) mice compared to wild type mice after allergen treat-
ment. Consistently, we could also detect an increase in mast cells
in the lungs of these mice. IL-9 has been described to induce
SOCS3 which in turn inhibits IL-9. However, considering that
mast cells as well as T effector cells develop in the absence of
Tyk-2, it is possible that SOCS3 cannot inhibit IL-9 in Tyk-2(2/2)
mice. In fact, SOCS3 binds to Tyk-2 and JAK2/JAK1 downstream
of IL-9 and other cytokines using the same receptor c chain8,20,28. It
could be already demonstrated that IL-21 is expressed in activated
human CD41 T cells but not in most other tissues. Furthermore,
the expression of IL-21 is up-regulated in Th2 and Th17 subsets of
T helper cells, as well as T follicular helper (Tfh) cells. In addition,
IL-21 is expressed in NKT cells regulating the function of these
cells. A study using mice with peanut allergies showed that sys-
temic treatment with IL-21 effectively weaked the allergic res-
ponse36–39. In conclusion, the low levels of IL-21 in the BALF in
asthma could be consistent with the decreased production of this
cytokine by NKT cells thus favoring IgE development in allergy. By
contrast, the increase of IL-21 in lung CD41T cell supernatants
might reflect the expansion of the Thf and Th2 cells in asthma.
These Th17 cells however cannot be supported by IL-23 because it
was found decreased especially in Tyk-2(2/2) asthmatic mice.
IL-17A has been described to play a role in inducing airway hyper-
responsiveness40. Since Tyk-2(2/2) mice show a much more severe
asthmatic phenotype but no elevated AHR compared to wild-type
mice we applied this cytokine during allergen challenge. Wild-type
mice showed increased neutrophils in the BALF compared to Tyk-
2(2/2) mice after allergen challenge. Treatment with recombinant IL-
17A led to an increase in BAL neutrophils in both mouse strains
compared to respective OVA treated mice. However, this effect
was significantly stronger in wild type mice suggesting a reduced
recruiting capacity in Tyk-2(2/2) mice which was not rescued by
Figure 5 | Treatmentwith rIL-17A led to down-regulation of T regulatory cells in Tyk-2 deficientmice. (a).Mice were treated withOVA alone andOVA
1 rIL-17A as shown in the experimental design. (b).–(d). Lung CD41T cells from OVA alone and OVA 1 rIL-17A treated mice were isolated and
incubated for 24 h with a-CD3 and a-CD28. The supernatants were analyzed by ELISA for IL-4, IL-5 and IL-13 ((b):IL-4: n 5 3–4; p 5 0.004; p 5 0.003;
(c): IL-5: n5 3–4; p5 0.0002; p5 0.040; (d): IL-13: n5 3–4; p5 0.002; p5 0.018; p5 0.017). (e). BALFwas retrieved and BAL cells were incubated with
antibodies against CD3, CD45R, CCR3 and Gr-1 and subsequently analyzed by flow cytometry. CD32CD45R2CCR32Gr-11 cells were counted as
neutrophils ((b). n 5 3–4; p 5 0.039; p 5 0.029; p 5 0.036; p 5 0.015). (f). Total lung cells fromOVA and OVA 1 rIL-17A treated mice were incubated
with antibodies against CD4, CD25 and Foxp3 and analyzed by flow cytometry (n 5 3–4; p 5 0.001; p 5 0.002). (g). Lung CD41T cells fromOVA alone
and OVA 1 rIL-17A treated mice were isolated and incubated for 24 h with a-CD3 and a-CD28. The supernatants were analyzed by ELISA for IL-9
(n 5 2–3; p 5 0.0004; p 5 0.016).
www.nature.com/scientificreports
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exogenous IL-17A.Moreover, IL-17A treatment led to a reduction in
Th2 cytokine production in Tyk-2(2/2) mice while the production
was not altered in wild type mice. In accordance with the findings
from Bettelli and co-workers we think that IL-17A is able to block
Th2 cytokine production in a Tyk-2-dependent manner31. Also, IL-
17A led to a down-regulation of regulatory T cells in Tyk-2(2/2) mice,
while their number in thewild-type littermates remained unchanged.
These data are consistent with an up-regulation of SOCS3 in the lung
of Tyk-2 deficient mice. IL-9 was found unchanged in lung CD41 T
cells before and after in vivo rIL-17A treatment of Tyk-2(2/2) mice
suggesting that IL-17A does not influence directly IL-9 production in
T cells41.
Altogether, these results demonstrate a reduced survival fitness of
the Th17 in the absence of Tyk-2 mediated by the up-regulation of
SOCS3 that should be considered for a therapeutic setting in allergy
as well as in autoimmune diseases and cancer.
Methods
All methods were carried out in accordance with the approved guidelines.
Mice. Tyk-2(2/2) and wild-type mice on a Balb/c genetic background were used at the
age of 6 to 8 weeks. All experiments were undertaken with the approved licenses (23-
177-07/G09-1-008, 23177-07/051-1V2 from ethical Review Board; Rheinland-Pfalz
and 54-2532.1-2/10 from Bavaria). One to three independent experiments were
performed, one representative experiment is shown.
OVA sensitization and challenge. Female Tyk-2(2/2) and wild-type mice on a Balb/c
background were maintained under specific pathogen-free conditions and received
i.p. injections of 500 mg/ml ovalbumin (Calbiochem, Gibbstown, NJ) complexed with
10% alum (Sigma-Aldrich, Steinheim, Germany) on days 0 and 7 as previously
described42,43. On days 18, 19 and 20 the animals received ovalbumin in PBS via
aerosol (10 mg ovalbumin/ml PBS in aerosol solution) for 30 minutes in a chamber
connected to an aerosol generator (Fo¨hr Medical Instruments, Seeheim, Germany).
Twenty-four hours after the last aerosol, invasive whole-body plethysmography was
performed tomeasure airway resistance andmice were sacrificed afterwards to isolate
lung or spleen cells as previously described. For recombinant IL-17A treatment mice
were anaesthetized 60 minutes before allergic challenge was performed and given
100 ng (IL-17A) intranasally on days 18, 19 and 20.
Assessment of AHR and collection and analysis of bronchoalveolar lavage. To
measure airway reactivity, we used whole-body plethysmography as previously
described43,44. Data are expressed as mean values of ‘‘airway resistance [RI]/baseline
RI’’ 6 SEM. After plethysmography, bronchoalveolar lavage of the right lung was
performed twice with 800 mL saline each. BALF supernatants were frozen and
subsequently analyzed by ELISA. The cell pellet was resuspended in PBS and counted
(CASYH TT, Roche Diagnostics, Mannheim, Germany) and subsequently used for
cytospin analysis after staining with May-Gru¨nwald-Giemsa solution (Carl Roth,
Karlsruhe, Germany) or for Flow Cytometric Analysis (FACS).
Histology. Lungswere removed, fixed in 10% formalin-PBS solution, dehydrated and
embedded in paraffin. 5 mm thick sections were stained with Masson-Goldner
staining for quantification of collagen deposition45 or with Toluidine Blue for mast
cell staining.
Isolation and analysis of lung and spleen CD41T cells and cell culture. Lung CD41
T cells were positively sorted by magnetic bead isolation (MACS, Miltenyi Biotec,
Bergisch-Gladbach) according to the manufacturer’s protocol.
In some experiments lung and spleen CD41 T cells were incubated with anti-CD3
(2 mg/ml), anti-CD28 (2 mg/ml). Antibodies were fromhybridoma cell cultures. After
24 hours, or later as indicated, the supernatants were removed and analyzed by ELISA
and RNA extracted from the cells.
Th17 skewing of spleen cells. Spleens were removed from naı¨ve Tyk-2 and Balb/c
mice and CD41CD62L1 were positively sorted by magnetic bead isolation (MACS,
Miltenyi Biotec, Bergisch-Gladbach) according to the manufacturer’s protocol. Cells
were plated at a concentration of 1 Million per ml and were incubated with plate-
bound anti-CD3 (2 mg/ml), anti-IL-4 (10 mg/ml), anti-IFNc (10 mg/ml), TGF-b
(3 ng/ml) and anti-CD28 (2 mg/ml) antibodies. Additionally cells received 20 ng/ml
recombinant IL-6 with or without 80 ng/ml of recombinant IL-21 or 50 ng/ml of
recombinant IL-23. After three days IL-2 was added and on day 5 supernatants were
frozen.
Flow cytometric analysis, intracellular staining and proliferation assay. Total lung
cells were stained with antibodies for 30 min at 4uC, washed in PBS, and then
analyzed on a FACS-Calibur (BD Pharmingen, Heidelberg, Germany). The following
FITC-, PE-, PerCP or APC-conjugated monoclonal antibodies were used for flow
cytometry: CCR3, CD3, CD4 (L3T4), CD25, CD45R, Gr-1, Foxp3, IL-17A, ckit and
FceRI. Antibodies were purchased from BD Pharmingen (BD Pharmingen,
Heidelberg, Germany), Miltenyi Biotec (Miltenyi Biotec, Bergisch-Gladbach) or
eBioscience (eBioscience, Frankfurt, Germany).
For intracellular staining for Foxp3 cells were stained with anti-CD4 (L3T4; BD
Pharmingen) and anti-CD25 (BD Pharmingen, Heidelberg, Germany) antibodies for
30 min at 4uC. Afterwards, cells were fixed with fixation/permeabilization solution
(eBioscience, Frankfurt, Germany) for 35 min at 4uC and washed with permeabili-
zation buffer (eBioscience, Frankfurt, Germany). Cells were then incubated with
antibodies against Foxp3 (Miltenyi Biotec, Bergisch-Gladbach, Germany) for 30 min
at 4uC in permeabilization buffer and washed once.
For intracellular staining of IL-17A, freshly isolated lung cells were incubated over
night with anti-CD3 and anti-CD28 at 37uC. Then they were stimulated with 1 ng/ml
PMA (Sigma-Aldrich, Steinheim, Germany), 1 mM Ionomycin (Sigma-Aldrich,
Steinheim, Germany), and GolgiStop (BD Pharmingen, Heidelberg, Germany) for
4 h. After harvesting cells, the same protocol as for Foxp3 staining was used.
Furthermore, a proliferation assay with CD41lung cells was performed as prev-
iously described25.
ELISA. Mouse IL-3 (7.8–500 pg/ml), IL-4 (7.48–500 pg/ml), IL-5 (15.6–1000 pg/
ml), IL-6 (15.6–1000 pg/ml), IgE (1.6–100 ng/ml), IgG2a (3.1–200 ng/ml) and IL-10
(31.3–2000 pg/ml), were detected by using a specific sandwich ELISA (OptEIA; BD
Pharmingen, Heidelberg, Germany). ELISA kits for mouse IL-1b (15.6–1000 pg/ml),
IL-13 (15.6–1000 pg/ml) IL-17A (15.6–1000 pg/ml), IL-17F (23.4–1500 pg/ml), IL-
21 (62.5–4000 pg/ml), IL-23 (39.1–2500 pg/ml) and TGF-b (15.6–1000 pg/ml) were
from DuoSet; R&D, Wiesbaden, Germany. IL-9 (30–4000 pg/ml) was determined
using a Ready!Set!Go! from eBioscience (Frankfurt, Germany).
qPCR. Lungs were removed and stored in peqGold RNA Pure (peqlab, Erlangen,
Germany) at 280uC until analysis. Tissue was homogenized in peqGold RNA Pure
and used for RNA extraction according to the manufacturer’s protocol. Cells were
also lysed directly on the cell culture plate and taken for RNA extraction. Briefly, cells
were treated with chloroform (Roth, Karlsruhe, Germany) and RNAwas precipitated
with isopropanol (Roth, Karlsruhe, Germany). RNA concentration in each sample
was determined using a spectrophotometer (Nanodrop, peqlab, Erlangen, Germany).
One mg of RNA was reverse-transcribed to cDNA using the RevertAidTM First Strand
cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany) according to the
instructions. Twenty ng of cDNA was used in each reaction and added to 23
SsoFastTM EvaGreenH Supermix (BIO-RAD,Munich, Germany) and 200 nMprimer.
Murine primers for IL-9 (fwd: 59-CTG ATG ATT GTA CCA CAC CGT GC-39, rev:
59-GCC TTT GCA TCT CTG TCT TCT GG-39), Irf4 (fwd: 59-ACG CTG CCC TCT
TCA AGG CTT-39, rev: 59-TGG CTC CTC TCG ACC AAT TCC-39), IL-17A (fwd:
59-TCCAGAAGGCCCTCAGACTA, rev: 59-AGCATCTTCTCGACCCTGAA-
39), Pu.1 (fwd: GCA TCT GGT GGG TGG ACA A, rev: TCT TGC CGT AGT TGC
GCA G), Socs3 (fwd: GTT CCT GGA TCA GTA TGA TGC, rev: CGC TTG TCA
AAG GTA TTG TCC), Stat5 (fwd: CGC TGG ACT CCA TGC TTC TC, rev: GAC
GTG GGC TCC TTA CAC TGA) and as controlHprt (for: 59-GCC CCA AAA TGG
TTA AGG TT-39, rev: 59-TTG CGC TCA TCT TAG GCT TT-39) were purchased
from Eurofins-MWG-Operon, Ebersberg, Germany. qPCR was run on CFX-96 Real-
Time PCRDetection System (BIO-RAD,Munich, Germany), and analyzed with CFX
Manager Software.
Statistical analysis. Differences were evaluated for significance (* p # 0.05; ** p #
0.01, *** p # 0.001) with the Student-two-tailed t test for independent events by
using statistical analysis (Excel, Microsoft, version 2003). Data are given as mean
values 6 SEM.
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